Arca
Skip to content
Tools
Tools

Hemophilia A

Drug research and approvals for hemophilia A: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 83 studies of hemophilia A are recruiting on ClinicalTrials.gov, Health Canada has authorized 47 drug trials for it since 2013, FDA has 19 approved and 25 open orphan designations naming it, and the EU has 18 authorised medicines for it.

  • Recruiting worldwide: 83
  • Trials authorized in Canada: 47
  • FDA orphan approvals: 19
  • EU medicines: 18

Recruiting now

Newest posted first, of 83 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 19

Phase 3 6

Phase 2 7

Phase 1 or earlier 8

How its trials ended

834 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 214 whose ending is known, 64% met their primary endpoint, 0% missed it and 36% stopped early.

  • Completed, result not reported36243%
  • Ongoing17121%
  • Met its primary endpoint13716%
  • Status unknown8710%
  • Stopped: other or unclear435%
  • Stopped: sponsor or business decision213%
  • Stopped: enrollment or feasibility81%
  • Stopped: lack of efficacy2<1%
  • Missed its primary endpoint1<1%
  • Stopped: safety1<1%
  • Stopped: funding1<1%

Trials authorized in Canada

The 10 newest of 47; search them all in Canada trials
Aug 18, 2026A multicenter, open-label, single-arm, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis…NXT007 (RO7589655)RochePending
Jun 18, 2026A multinational, open-label study to investigate efficacy and safety of denecimig (MIM8) in adults with acquired haemophilia AMIM8 / NNC0365-3769Novo NordiskPending
Mar 26, 2026A multicenter, randomized, open-label, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis…NXT007 (RO7589655) / Eloctate / Adynovate / Esperoct / Xyntha / Kovaltry / JiviRochePending
Mar 18, 2026A multicenter, randomized, open label, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis…NXT007 (RO7589655) / Hemlibra [emicizumab (RO5534262)]RocheOngoing
Aug 20, 2025An open-label, parallel, phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12…Fitusiran (SAR439774)Sanofi-Aventis Canada IncOngoing
May 9, 2025A phase 1 single and multiple dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SR604 in healthy…SR604Equilibra Bioscience LLCClosed
Feb 27, 2025A phase 1 b open-label non-randomized study to assess the safety, pk &pd of marstacimab treatment following the discontinuation of emicizumab therapy in…MarstacimabPfizerClosed
Dec 12, 2024Synoviiius: prospective interventional study of effectiveness of efanesoctocog alfa prophylaxis on synovial hypertrophy in patients with hemophilia ABIVV001 (efanesoctocog alfa)SanofiOngoing
Jul 4, 2024A phase 3, single-arm, open-label, multicenter study of the safety and efficacy of dirloctocogene samoparvovec (SPK-8011, adeno-associated viral vector with…Dirloctocogene samoparvovec (SPK-8011) / Cellcept / MethylprednisoloneSpark TherapeuticsPending
Sep 27, 2023Open-label, long-term safety and efficacy study of MIM8 in participants with haemophilia A with or without inhibitorsMIM8Novo NordiskOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 44
Jun 5, 2026HympavziRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with…Pfizer Inc.Approved
Jul 31, 2025AlhemoRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Novo Nordisk, Inc.Approved
Mar 28, 2025QfitliaFor routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older…Genzyme CorporationApproved
Mar 28, 2025QfitliaRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with…Genzyme CorporationApproved
Dec 20, 2024AlhemoRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Novo Nordisk, Inc.Approved
Oct 11, 2024HympavziRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with…Pfizer Inc.Approved
Jun 29, 2023RoctavianTreatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity less than 1 IU/dL) without…BioMarin Pharmaceutical, Inc.Approved
Feb 22, 2023AltuviiioIn adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding…Bioverativ Therapeutics, Inc.Approved
Oct 4, 2018HemlibraHEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages…GenentechApproved
Nov 16, 2017HemlibraRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital…GenentechApproved
Oct 23, 2014ObizurTreatment of bleeding episodes in adults with acquired hemophilia A.Takeda Development Center Americas, Inc.Approved
Jun 6, 2014EloctateIndicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding…Bioverativ Therapeutics, Inc.Approved
Dec 16, 2013FeibaRoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitorsTakeda Pharmaceuticals U.S.A., Inc.Approved
Aug 12, 2005NovoSevenPrevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or…Novo Nordisk, Inc.Approved
Mar 6, 2000ReFacto, XynthaFor the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII…Wyeth Pharmaceuticals, Inc.Approved

Medicines authorised in the EU

Newest first; 15 of 18
Dec 13, 2024AlhemoConcizumabNovo Nordisk A/SEMA ↗
Nov 18, 2024HympavziMarstacimabPfizer Europe MA EEIGEMA ↗
Jun 17, 2024AltuvoctEfanesoctocog alfa · orphanSwedish Orphan Biovitrum AB (publ)EMA ↗
Jul 15, 2022CevenfactaEptacog beta (activated)Laboratoire Francais du Fractionnement et des BiotechnologiesEMA ↗
Jun 20, 2019EsperoctTuroctocog alfa pegolNovo Nordisk A/SEMA ↗
Nov 22, 2018JiviDamoctocog alfa pegolBayer AGEMA ↗
Feb 23, 2018HemlibraEmicizumabRoche Registration LimitedEMA ↗
Jan 8, 2018AdynoviRurioctocog alfa pegolBaxalta Innovations GmbHEMA ↗
Feb 13, 2017VihumaSimoctocog alfaOctapharma ABEMA ↗
Jan 4, 2017AfstylaLonoctocog alfaCSL Behring GmbHEMA ↗
Feb 18, 2016KovaltryOctocog alfaBayer AGEMA ↗
Nov 18, 2015EloctaEfmoroctocog alfaSwedish Orphan Biovitrum AB (publ)EMA ↗
Nov 11, 2015ObizurSusoctocog alfaBaxalta Innovations GmbHEMA ↗
Jul 22, 2014NuwiqSimoctocog alfaOctapharma ABEMA ↗
Nov 13, 2013NovoEightTuroctocog alfaNovo Nordisk A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.